biologic

Unituxin

dinutuximab

Loss of exclusivityMarch 2027projected — 12-year biologic exclusivity estimate
CompanyUnited Therapeutics Corporation

Drug detail

Brand nameUnituxin
Active ingredientdinutuximab
Strength17.5MG/5ML (3.5MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Unituxin patent cliff — loss of exclusivity March 2027 | CliffBio